Key Market Indicator:
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 25.06.2025
https://research-hub.de/companies/Nordex SE
Nordex has announced a major 435.2 MW order from German developer UKA in Q2, including 64 turbines and 20-year service contracts, one of its largest domestic deals. A 160 MW order from Turkey was also announced today. Earlier in the quarter, several smaller contracts in Germany and France were secured. Together, these deals point to strong Q2 order momentum. Demand remains robust, supported by a solid pipeline into late 2024 and early 2025, with an order backlog nearly twice the company’s annual revenue. As Nordex typically announces more deals at quarter-end, further Q2 orders are likely. The strong intake underscores Nordex’s solid position in the expanding European onshore wind market, particularly in Germany. mwb research’s analysts maintain their BUY rating and PT of EUR 20.00, confident in growth and improving profitability, though our midterm estimates remain conservative for now versus the company’s mid-term targets. The full update can be downloaded under https://www.research-hub.de/companies/Nordex%20SE.
Wed, 25.06.2025
https://research-hub.de/companies/Carl Zeiss Meditec AG
Carl Zeiss Meditec (CZM) remains a global leader in ophthalmic and microsurgical technologies, supported by secular growth drivers such as ageing demographics and rising vision disorders. Despite cyclical headwinds in hospital spending and macro uncertainties, the business benefits from a resilient, growing base of recurring revenues. New platforms like KINEVO and VISUMAX, coupled with a good order backlog, provide near-term momentum. While management maintains a cautious FY outlook, current valuation appears compelling after a sharp stock decline by c. 15% since mid-May. With the share price now well below our EUR 65.00 target, mwb research’s analysts upgrade the rating from HOLD to BUY, anticipating margin recovery and product-driven growth. The full update can be downloaded under https://www.research-hub.de/companies/Carl%20Zeiss%20Meditec%20AG
Tue, 24.06.2025
HORNBACH Holding AG & Co. KGaA
Company Name:
HORNBACH Holding AG & Co. KGaA
ISIN:
DE0006083405
Reason for the research:
Update
Recommendation:
Buy
from:
24.06.2025
Target price:
110.00
Last rating change:
Analyst:
Ralf Marinoni
Q1-25/26: strong increase of sales, earnings and cash flowHORNBACH Holding started strong into the current business year; in our [ … ]
Tue, 24.06.2025
Vidac Pharma Holding Plc
Company Name:
Vidac Pharma Holding Plc
ISIN:
GB00BM9XQ619
Reason for the research:
Update Report
Recommendation:
Buy
from:
24.06.2025
Target price:
EUR 4.30 (previously: EUR 4.90)
Target price on sight of:
36 months
Last rating change:
-
Analyst:
Peter Thilo Hasler
Vidac Pharma recently announced encouraging pharmacokinetic r [ … ]
Tue, 24.06.2025
PFISTERER Holding SE
Company Name:
PFISTERER Holding SE
ISIN:
DE000PFSE212
Reason for the research:
Research study (Initial Coverage)
Recommendation:
BUY
Target price:
48.00 EUR
Target price on sight of:
31.12.2025
Last rating change:
Analyst:
Cosmin Filker, Marcel Goldmann
You can download the research here: http://www.more-ir.de/d/32900.pdf
Co [ … ]
Tue, 24.06.2025
Netfonds AG
Company Name:
Netfonds AG
ISIN:
DE000A1MME74
Reason for the research:
Update
Recommendation:
Buy
from:
24.06.2025
Target price:
EUR 78.00
Target price on sight of:
12 months
Last rating change:
Analyst:
Frederik Jarchow
Strong start into FY25 // Guidance upgrade; chg
Netfonds reported promising Q1 figures indicating that the [ … ]
Tue, 24.06.2025
https://research-hub.de/companies/Stratec SE
Stratec’s inclusion in the SDAX on June 25, 2025, enhances its visibility ahead of the mwb research Health Care Conference on July 1, where CEO Markus Wolfinger will outline the company’s strategic direction. The event offers timely insight into Stratec’s shift toward high-margin, service-based revenues and platform development. Investors are encouraged to register here: research-hub.de/conference/health-care-conference. As management confirmed its FY25 guidance, with an adjusted EBIT margin of 10–12%, mwb research’s analysts maintain their BUY rating and reaffirm their EUR 32.50 price target, implying an attractive upside. The analysts believe, the SDAX entry could act as a catalyst for increased investor attention and a rerating of the shares. The full update can be downloaded under https://research-hub.de/companies/research/Stratec%20SE
Tue, 24.06.2025
https://research-hub.de/companies/Verbio SE
Verbio’s removal from the SDAX on June 23 triggered some short-term technical selling and reduced liquidity from index-tracking funds. However, despite the announcement on June 4, the share price rose by more than 20%, suggesting the market viewed this as a temporary dislocation. Meanwhile, US policy momentum in June 2025, driven by higher Environmental Protection Agency (EPA) biofuel mandates and regulatory clarity, aligns well with Verbio’s strategy. The company’s Nevada-based RNG and bioethanol facility stands to benefit from stronger demand and domestic supply preferences. With deep expertise in biofuels and vertical integration, Verbio is well positioned for growth. While European operations remain stable, the US expansion offers the clearest nearterm upside. US regulatory support and full-scale ramp-up in Nevada could be key catalysts for re-rating. mwb research’s analysts reiterate their BUY rating and maintain their PT of EUR 15.00. The full update can be downloaded under https://www.research-hub.de/companies/Verbio%20SE
Tue, 24.06.2025
Desert Gold Ventures Inc.
Company Name:
Desert Gold Ventures Inc.
ISIN:
CA25039N4084
Reason for the research:
Management Interview
Recommendation:
Buy
Target price:
0.311 USD
Last rating change:
Analyst:
Matthias Greiffenberger, Cosmin Filker
GBC AG: The Tiegba project marks Desert Gold’s expansion into the Republic of Côte d’I [ … ]
Mon, 23.06.2025
CLINUVEL Pharmaceuticals
Company Name:
CLINUVEL Pharmaceuticals
ISIN:
AU000000CUV3
Reason for the research:
Research Update
Recommendation:
Buy
from:
23.06.2025
Target price:
22.00 AU$
Target price on sight of:
12 month
Last rating change:
none
Analyst:
Thomas Schiessle, Daniel Großjohann
CEO Dr. Philippe Wolgen back on board – SCENESSE® [ … ]